Open AccessP929: IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I‐DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM).
Author(s) -
Macro M.,
Touzeau C.,
Mariette C.,
Manier S.,
Brechignac S.,
Vincent L.,
Hebraud B.,
Decaux O.,
Schulmann S.,
Lenoir C.,
Godmer P.,
Farge A.,
Peyro Saint Paul L.,
Parienti J.J.,
Leleu X.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846584.41392.46
Subject(s) - medicine , daratumumab , lenalidomide , ixazomib , tolerability , multiple myeloma , clinical endpoint , adverse effect , discontinuation , bortezomib , phases of clinical research , oncology , surgery , clinical trial , carfilzomib